RxDoctor Payments Data

David Boone, DO

Ophthalmology · Macon, GANPI 1093798753

Payments from drug & device makers

$7,064in general payments, 2019–2025

Across 217 payments — averaging $32.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • AbbVie$713
  • Sun Pharmaceutical Industries Inc.$380
  • Bausch & Lomb Americas Inc.$338
  • Alcon$240
  • Amgen$103
  • plus $368 from 10 others

What the payments were for

  • Speaking & faculty fees$451%
  • Food & beverage$6,75896%
  • Education$891%
  • Gifts$1732%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,064 in reported general payments places this provider in the 75th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$227,841
Medicare patients
595
Services billed
1,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost394$220,908
CombiganBrimonidine Tartrate/Timolol187$89,147
Alphagan PBrimonidine Tartrate73$36,858
Latanoprost1,657$18,971
AzoptBrinzolamide25$15,590
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol57$13,638
SimbrinzaBrinzolamide/Brimonidine Tart23$11,685
VyzultaLatanoprostene Bunod26$10,889
Travoprost55$9,243
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat508$8,571
RocklatanNetarsudil Mesylat/Latanoprost11$7,952
Brimonidine Tartrate215$7,188
Timolol Maleate313$5,897
Dorzolamide Hcl101$3,079
Dorzolamide-TimololDorzolamide/Timolol/Pf16$2,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$713$346,913654 claims
AlconAzopt, Simbrinza$240$27,27648 claims
Bausch & Lomb Americas Inc.Vyzulta$338$10,88926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Macon

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →